MGL-2086
Undisclosed
Phase 1Expected 2Q26
Key Facts
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapeutics for MASH, formerly known as NASH. The company has successfully brought the first FDA-approved treatment for MASH to market in the U.S. and EU, marking a historic milestone in liver disease treatment. Madrigal's innovative THR-β agonist platform addresses the underlying causes of liver fibrosis and metabolic dysfunction, with multiple Phase 3 trials ongoing to expand treatment options for MASH patients.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| ASPEN Study Program | Insmed | Phase 3 |
| ARISE Study Program | Insmed | Phase 3 |
| Innovative Proprietary/Licensed Products | Laboratorios Farmaceuticos Rovi | Various |
| Undisclosed Partnered Program | Septerna | Discovery |
| Undisclosed Cell Therapy | Immix Biopharma | Pre-clinical |
| HTL0039732 | Nxera Pharma | Preclinical |
| LYT-310 | PureTech Health | Preclinical |
| Bispecific (Undisclosed) | MacroGenics | Preclinical |
| Sec61 Portfolio Assets | Kezar Life Sciences | Preclinical |
| WTX-518 | Werewolf Therapeutics | Preclinical |
| WTX-712 | Werewolf Therapeutics | Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |